Evidence map›Paper›PMID 42834997›Full record

ArticleMaterials today. Bio2026

Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles enhances anti-glioma therapy.

Yue Gong, Hufeng Fang, Xinrui Li, Sijia He, Zhenwei Ding, Yingying Xu, Tianyi Zhuang, Jiaxin Li, Wei Zhao, Hongli Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yue GongDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
Hufeng FangDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
Xinrui LiThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Sijia HeThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Zhenwei DingDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
Yingying XuDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
Tianyi ZhuangDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
Jiaxin LiDepartment of Pharmacy, The Affiliated Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, 214400, China.
Wei ZhaoThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Hongli LiuThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Xiang CaoThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Kefan SongThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Nan ShenDepartment of Pharmacy, The Affiliated Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, 214400, China.
Dan SuDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
Hongliang XinThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center of Nanjing Medical University, Pharmacy School of Nanjing Medical University, Nanjing, 211166, China.
Wei LvDepartment of Pharmacy, The Affiliated Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, 214400, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blood-brain barrier (BBB) remains a major obstacle to effective glioma chemotherapy, and although mesenchymal stem cell (MSC) membrane (MSCM) coated nanoparticles offer a biomimetic strategy for glioma-targeted delivery, the role of particle morphology in such systems remains unclear. Herein, doxorubicin-loaded mesoporous silica nanoparticles coated with MSC membranes (MSCM@MSN@DOX) were developed with three morphologies-spherical (AR∼1), short rod-shaped (AR∼1.5), and long rod-shaped (AR∼3) to study the shape effect of MSC biomimetic drug delivery system on glioma treatment. All formulations showed successful membrane coating, retention of MSC-associated proteins, and comparable drug loading, release, and stability, enabling assessment of shape-dependent delivery behavior. Compared with AR∼1 and AR∼1.5 counterparts, AR∼3 particles exhibited enhanced motility, higher uptake by bEnd.3 and GL261 cells, improved trans-BBB transport, and deeper tumor spheroid penetration. Mechanistic studies suggested that these effects were associated with stronger nanoparticle-cell membrane interactions and morphology-dependent endocytic behavior. In an intracranial GL261 glioma model, AR∼3 particles achieved greater brain/glioma-region accumulation, more pronounced tumor growth inhibition, and extended survival, with no overt systemic toxicity under the tested regimen. These findings identify particle morphology as an important optimization parameter within the investigated MSC membrane-coated MSN system and provide a basis for shape optimization of this biomimetic nanocarrier platform for brain-targeted drug delivery.

Indexed as

Brain-targeted drug deliveryGliomaMesoporous silica nanoparticlesMSC membrane biomimetic nanocarriersParticle morphology

Identifiers

PMID42834997
PMCPMC13634997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.